With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...

It estimates that more than 300,000 people take Humira in the US every year, with net revenues of the drug reaching $18 billion in 2022. MCCPDC’s proposition is somewhat different as it supplies ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

Employees at banking giant JPMorgan Chase claimed in a new class action suit that the company mismanaged their benefits, ...

Talks between CMS and drugmaker Amgen authorized under the Inflation Reduction Act (IRA), former President Biden's signature ...

You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of ...

So, you want to invest in AbbVie (NYSE: ABBV) because it's a promising dividend-paying stock, and you also want to receive $1 ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...